Unloxcyt (Cosibelimab-ipdl)

Unloxcyt (cosibelimab-ipdl) is a programmed death ligand-1 (PD-L1) blocking antibody used to treat adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

Recommended Dosage: The recommended dosage of Cosibelimab-ipdl is 1,200 mg administered as an intravenous (IV) infusion over 60 minutes every 3 weeks until there is evidence of disease progression or unacceptable toxicity.
Call your doctor right away if you miss or skip a dose. They will instruct you on what to do next regarding your treatment. Remember not to alter the timetable on your own.

• Cosibelimab is associated with serious immune-mediated adverse events such as pneumonitis, hepatitis, colitis, endocrinopathies, and nephritis. The latter is the most concerning as it could lead to permanent changes in kidney functions. Patients should be monitored closely. Treatment should be stopped if there is any life-threatening adverse event. Patients have to be checked regularly and treated aggressively with steroids or other immune-modifying drugs.
• Fever, chills, rash, or shortness of breath are examples of common infusion-associated symptoms that patients may experience. These reactions can also lead to more life-threatening symptoms involving allergy attacks. It is best to always administer the drug in a hospital or other healthcare facility. Patients who exhibit these symptoms should have the infusion slowed or stopped entirely until further care can be sought. Medical personnel should be standing by.
• Transplant patients can suffer adverse consequences after HSCT such as GVHD, hepatic veno-occlusive, or rejection of transplant. These factors must be considered when proceeding with HSCT after treatment with Cosibelimab. These complications should be looked out for after the transplant has taken place.
• Reproductive forecasts may get impeded due to the use of Cosibelimab 300 mg/5 mL. Women with a possibility of conceiving should take precautions like birth control when on therapy and five months post-therapy. Men are also advised to prevent conceiving as the medication may negatively impact fertility and conceiving.
• There is a possibility that Cosibelimab can damage a developing fetus. Pregnant women, unless the advantages outweigh the disadvantages, should refrain from the medication. Patients should be made aware of these risks. If a patient undergoing treatment for Cosibelimab becomes pregnant, stop treatment and administer appropriate counsel while monitoring closely.
• No breastfeeding should occur during treatment or for 5 months after treatment with Cosibelimab has ceased. It is not fully known if the medication is likely to be absorbed into breast milk and cause harm to the child. Explain options and issues that have resulted to mothers that breastfeed to patients.
• Cosibelimab-IPDL’s safety and efficacy have not been established in a pediatric population so it is not to be used in children unless specifically recommended by an experienced or qualified healthcare professional (HCP) who takes care of such conditions.

What documents are required to import UNLOXCYT to India?

UNLOXCYT (cosibelimab-ipdl) injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is UNLOXCYT available in India?

UNLOXCYT (cosibelimab-ipdl injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Unloxcyt in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

UNLOXCYT can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of UNLOXCYT (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Unloxcyt 300 mg/5 mL injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source UNLOXCYT (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Unloxcyt®?

Cosibelimab-ipdl is a Generic Name for the trade name drug Unloxcyt®.

What is the Manufacturer's Name of Unloxcyt®?

Unloxcyt® is manufactured by Checkpoint Therapeutics, Inc.

Is Unloxcyt® approved by the FDA?

Yes, Unloxcyt® is approved by the FDA. Date of first approval: December 13, 2024.

What is the dosage and form of Unloxcyt® supplied?

Unloxcyt is supplied in Injection: 300 mg/5 mL (60 mg/mL) solution in a single-dose vial for intravenous use.

What are the most common side effects of Unloxcyt® 300 mg/5 mL injections?

The most common side effects of Unloxcyt® are fatigue, headache, musculoskeletal pain, rash, diarrhea, nausea, hypothyroidism, constipation, pruritus, localized infection, edema, and urinary tract infection.

How much does Unloxcyt® 300 mg/5 mL injection cost in India?

Prices of Unloxcyt 300 mg/5 mL may fluctuate over time because of market dynamics and regulatory changes. To get the most transparent Unloxcyt 300 mg/5 mL injection cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Unloxcyt® 300 mg/5 mL injections be available in SAARC countries?

Apart from Gulf countries, Unloxcyt® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Unloxcyt® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Unloxcyt® 300 mg/5 mL injections online in India?

Yes, one can buy Unloxcyt 300 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Unloxcyt® injections through legal channels.

What are the storage conditions of Unloxcyt® 300 mg/5 mL injections?

Store in a refrigerator at 2-8°C (36-46°F) in original carton to protect from light. Do not freeze or shake.